Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse as Adjunctive Therapy in Major Depressive Disorder
NCT01435759Phase 2Completed
- Sponsor
- Takeda
- Start
- May 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of lisdexamfetamine in major depressive disorder (MDD) (5 arms), sponsored by Takeda. Primary endpoint: Montgomery-Ǻsberg Depression Rating Scale at 16 weeks. Started May 2011; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01435759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01435759.